UroGen Pharma (URGN) Misses Q4 EPS by 6c

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.84 million versus the consensus estimate of $41.45 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• UBS Reiterates Neutral Rating on Green Plains Renewable Energy (GPRE)
• Rush Enterprises Inc. (RUSHA) PT Raised to $85 at UBS